← All Kiora Pharmaceuticals INC filings

Kiora Pharmaceuticals INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
KPRX
Kiora Pharmaceuticals INC
10-K: Kiora Pharmaceuticals Reports 2025 Loss Amid R&D Investments
Kiora Pharmaceuticals reported a net loss of $10.8 million for 2025, driven by increased R&D spending on its KIO-104 and KIO-301 programs and an impairment charge, despite securing key partnerships and maintaining liquidity into late 2027.
NASDAQ
KPRX
Kiora Pharmaceuticals INC
10-K: Kiora Pharmaceuticals Reports Fiscal Year 2024 Results, Highlights KIO-301 Partnership and Clinical Advancements
Kiora Pharmaceuticals announces its FY2024 results, marked by a strategic partnership with TOI for KIO-301 and progress in clinical trials for retinal diseases.
NASDAQ
KPRX
Kiora Pharmaceuticals INC
10-K: Kiora Pharmaceuticals Reports Full Year 2023 Results, Highlights Strategic Partnership and Pipeline Progress
Kiora Pharmaceuticals' 2023 annual report details a year of strategic shifts, clinical trial advancements, and a significant partnership to propel its retinal disease therapies.